kauliv
strides pharma (cyprus) limited - teriparatíð - osteoporosis; osteoporosis, postmenopausal - kalsíumsterastasis - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
atorvastatin xiromed (tinavast) filmuhúðuð tafla 80 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 80 mg
atorvastatin xiromed (tinavast) filmuhúðuð tafla 20 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 20 mg
atorvastatin xiromed (tinavast) filmuhúðuð tafla 10 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 10 mg
atorvastatin xiromed (tinavast) filmuhúðuð tafla 40 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 40 mg
rosuvastatin xiromed filmuhúðuð tafla 20 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg
rosuvastatin xiromed filmuhúðuð tafla 10 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg
rosuvastatin xiromed filmuhúðuð tafla 5 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg
rosuvastatin xiromed filmuhúðuð tafla 40 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - Æxlishemjandi lyf - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.